On January 21, Allist Pharmaceuticals stated in response to investor inquiries on an interactive platform that the company has long been committed to the research and development of small-molecule innovative drugs.

Building on the foundation of consolidating and enhancing its small-molecule drug R&D capabilities, the company has, in recent years, established a large-molecule drug discovery team and built a large-molecule drug R&D platform to further boost the innovation vitality of its research team.

Multiple early-stage research projects within the company's large-molecule team are progressing efficiently and in an orderly manner.

Currently, two products have entered the CMC development stage, with the hope of submitting an IND application as soon as possible.